|
|
Volumn 5, Issue 2, 2013, Pages 178-201
|
|
IBC's 23rd Annual Antibody Engineering, 10th Annual Antibody Therapeutics International Conferences and the 2012 Annual Meeting of the Antibody Society December 3-6, 2012, San Diego, CA
a
b
c
d
e
f
g
h
i
i
j
b
Covagen AG
*
(Switzerland)
|
|
Author keywords
Antibody engineering; Antibody therapeutics; Antibody drug conjugates; Bispecific antibodies; Computational design
|
|
Indexed keywords
AMYLOID BETA PROTEIN ANTIBODY;
ANTIBODY CONJUGATE;
ANTINEOPLASTIC AGENT;
BISPECIFIC ANTIBODY;
BLINATUMOMAB;
CETUXIMAB;
CYCLIC AMP DEPENDENT PROTEIN KINASE ANCHORING PROTEIN;
DOXORUBICIN;
EPIDERMAL GROWTH FACTOR RECEPTOR 2;
EPITHELIAL CELL ADHESION MOLECULE;
ERYTHROCYTE ANTIGEN;
HUMAN IMMUNODEFICIENCY VIRUS VACCINE;
IMMUNOGLOBULIN F(AB) FRAGMENT;
IMMUNOGLOBULIN G1 ANTIBODY;
INOTUZUMAB OZOGAMICIN;
MONOCLONAL ANTIBODY;
NANOBODY;
NEUTRALIZING ANTIBODY;
OFATUMUMAB;
PERTUZUMAB;
PGT 121;
PROSTATE SPECIFIC MEMBRANE ANTIGEN;
PSMA ADC;
RITUXIMAB;
ROZROLIMUPAB;
TENASCIN;
TRASTUZUMAB;
UNCLASSIFIED DRUG;
UNINDEXED DRUG;
VEDOLIZUMAB;
VIRUS ANTIBODY;
ACUTE LYMPHOBLASTIC LEUKEMIA;
ADAPTIVE IMMUNITY;
ALZHEIMER DISEASE;
AMYLOID PLAQUE;
ANGIOGENESIS;
ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY;
ANTIBODY ENGINEERING;
ANTIBODY LIBRARY;
ANTIBODY TITER;
ANTIGEN ANTIBODY COMPLEX;
ANTIGEN BINDING;
ANTINEOPLASTIC ACTIVITY;
AUTOIMMUNE DISEASE;
BLOOD BRAIN BARRIER;
CANCER INHIBITION;
CASTRATION RESISTANT PROSTATE CANCER;
CENTRAL NERVOUS SYSTEM;
CHRONIC PAIN;
CIRCULATING TUMOR CELL;
CONFERENCE PAPER;
CYTOTOXIC T LYMPHOCYTE;
CYTOTOXICITY;
DEGENERATIVE DISEASE;
DNA SEQUENCE;
ENDOTHELIUM CELL;
FOLLICULAR LYMPHOMA;
GENETIC VARIABILITY;
HIGH THROUGHPUT SEQUENCING;
HUMAN;
HUMORAL IMMUNITY;
IMMUNOMODULATION;
IMMUNOTHERAPY;
MAXIMUM TOLERATED DOSE;
MINIMAL RESIDUAL DISEASE;
MOLECULARLY TARGETED THERAPY;
NEUROFIBRILLARY TANGLE;
NEUROPROTECTION;
NEUTROPENIA;
NONHODGKIN LYMPHOMA;
NONHUMAN;
PARKINSON DISEASE;
PATENT;
PHAGE DISPLAY;
PHASE 1 CLINICAL TRIAL (TOPIC);
PHASE 2 CLINICAL TRIAL (TOPIC);
PHASE 3 CLINICAL TRIAL (TOPIC);
PROTEIN INTERACTION;
SEQUENCE ANALYSIS;
STOP CODON;
T LYMPHOCYTE ACTIVATION;
TRANSCYTOSIS;
TUMOR MICROENVIRONMENT;
TUMOR XENOGRAFT;
ANTIBODY ENGINEERING;
ANTIBODY THERAPEUTICS;
ANTIBODY-DRUG CONJUGATES;
BISPECIFIC ANTIBODIES;
COMPUTATIONAL DESIGN;
ANIMALS;
ANTIBODIES, BISPECIFIC;
ANTIBODIES, MONOCLONAL;
CELL LINE;
HALF-LIFE;
HUMANS;
IMMUNOCONJUGATES;
IMMUNOMODULATION;
MICE;
NEOPLASMS;
PROTEIN ENGINEERING;
|
|
EID: 84876553022
PISSN: 19420862
EISSN: 19420870
Source Type: Journal
DOI: 10.4161/mabs.23655 Document Type: Conference Paper |
|
Times cited : (8)
|
|
References (6)
|
